We narrowed to 1,077 results for: aav

#26973-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-hChR2(H134R)-EYFP (#26973). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-EYFP plasmid DNA. hSyn-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 27, 2024

Academic Institutions and Nonprofits only

#198511-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-DIO-PdCO-mScarlet-WPRE (#198511). In addition to the viral particles, you will also receive purified pAAV_hSyn-DIO-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven Cre-dependent expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

Sept. 27, 2024

Academic Institutions and Nonprofits only

#125707-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-RdLight1 (#125707). In addition to the viral particles, you will also receive purified pAAV-CAG-RdLight1 plasmid DNA. CAG-driven expression of red genetically encoded dopamine sensor RdLight1. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Nat Methods. 2020 Nov;17(11):1147-1155.

Feb. 16, 2024

Academic Institutions and Nonprofits only

#135631-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-GFP-fGFP (#135631). In addition to the viral particles, you will also receive purified pAAV-S5E2-GFP-fGFP plasmid DNA. Bicistronic expression of GFP and membrane-targeted GFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Sept. 27, 2023

Academic Institutions and Nonprofits only

#137153-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-NpHR3.3-EYFP (#137153). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-NpHR3.3-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of NpHR3.3-EYFP (inhibited in presence of Flp) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only

#83895-AAV1

Ready-to-use AAV1 particles produced from pAAV-hDlx-Flex-GFP-Fishell_6 (#83895). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-GFP-Fishell_6 plasmid DNA. hDlx-driven, Cre-dependent expression of GFP. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 2, 2020

Academic Institutions and Nonprofits only

#105531-AAV8

Ready-to-use AAV8 particles produced from pAAV.CMV.LacZ.bGH (#105531). In addition to the viral particles, you will also receive purified pAAV.CMV.LacZ.bGH plasmid DNA. CMV-driven LacZ expression control. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#176754-AAV1

Ready-to-use AAV1 particles produced from AAV-mDlx-jGCaMP8m-WPRE (#176754). In addition to the viral particles, you will also receive purified AAV-mDlx-jGCaMP8m-WPRE plasmid DNA. mDlx enhancer-driven expression of calcium sensor GCaMP8m in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#218877-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-syn-flex-iGABASnFR2-WPRE (#218877). In addition to the viral particles, you will also receive purified pGP-AAV-syn-flex-iGABASnFR2-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al eLife. 2026 Mar 18;14:RP108319. doi: 10.

Sept. 27, 2024

Academic Institutions and Nonprofits only

#104052-AAVPHP.V1

Ready-to-use AAV PHP.V1 particles produced from pAAV-CAG-DIO-EYFP (#104052). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-EYFP plasmid DNA. CAG-driven, Cre-dependent expression of EYFP. These AAV were produced with the PHP.V1 serotype, which permits efficient transduction of brain vascular cells. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

July 24, 2020

Academic Institutions and Nonprofits only

#104489-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-syn-jGCaMP7b-WPRE (#104489). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7b-WPRE plasmid DNA. Syn-driven jGCaMP7b calcium sensor. jGCaMP7b exhibits the brightest resting fluorescence of the jGCaMP7 variants and can be used for imaging of small neuronal processes. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Nov. 14, 2019

Academic Institutions and Nonprofits only

#105541-AAV5

Ready-to-use AAV5 particles produced from pENN.AAV.CamKII0.4.eGFP.WPRE.rBG (#105541). In addition to the viral particles, you will also receive purified pENN.AAV.CamKII0.4.eGFP.WPRE.rBG plasmid DNA. Expression of EGFP from CamKII promoter. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Aug. 2, 2018

Academic Institutions and Nonprofits only

#213936-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe4_dTomato_nlsdTomato (#213936). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the chandelier cell-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#105551-AAVrg

Ready-to-use AAV Retrograde particles produced from pENN.AAV.CamKII.HI.GFP-Cre.WPRE.SV40 (#105551). In addition to the viral particles, you will also receive purified pENN.AAV.CamKII.HI.GFP-Cre.WPRE.SV40 plasmid DNA. Expression of GFP-Cre from CamKII promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Oct. 21, 2024

Academic Institutions and Nonprofits only

#105553-AAV2

Ready-to-use AAV2 particles produced from pENN.AAV.hSyn.Cre.WPRE.hGH (#105553). In addition to the viral particles, you will also receive purified pENN.AAV.hSyn.Cre.WPRE.hGH plasmid DNA. hSyn-driven Cre expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Oct. 21, 2024

Academic Institutions and Nonprofits only

#37825-CAP-B22

Ready-to-use AAV CAP-B22 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV were produced with the CAP-B22 serotype, which permits efficient transduction of neurons and astrocytes in the central nervous system. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Nov. 8, 2023

Academic Institutions and Nonprofits only

#176751-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-CamKIIa-jGCaMP8m-WPRE (#176751). In addition to the viral particles, you will also receive purified AAV-CamKIIa-jGCaMP8m-WPRE plasmid DNA. CamKIIa-driven expression of calcium sensor GCaMP8m. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

July 21, 2023

Academic Institutions and Nonprofits only

#176750-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-CamKIIa-jGCaMP8f-WPRE (#176750). In addition to the viral particles, you will also receive purified AAV-CamKIIa-jGCaMP8f-WPRE plasmid DNA. CamKIIa-driven expression of calcium sensor GCaMP8f. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

July 21, 2023

Academic Institutions and Nonprofits only

#55638-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-vCre (#55638). In addition to the viral particles, you will also receive purified pAAV-EF1a-vCre plasmid DNA. EF1a-driven expression of VCre. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Nov. 12, 2020

Academic Institutions and Nonprofits only

#213941-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe3_ChR2_mCherry (#213941). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the PV+ basket cell-targeting enhancer E3. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only